| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
234 |
| Employees |
1,300 |
| Revenues (TTM) (Millions $) |
3,643 |
| Net Income (TTM) (Millions $) |
438 |
| Cash Flow (TTM) (Millions $) |
572 |
| Capital Exp. (TTM) (Millions $) |
82 |
Business Description
Horizon Therapeutics Public Limited Company is a biopharmaceutical company that focuses on researching, developing, and marketing treatments for rare and rheumatic diseases. The company was founded in 2008 and is headquartered in Dublin, Ireland, with US headquarters in Lake Forest, Illinois.
Horizon Therapeutics has a portfolio of innovative products, with a focus on orphan diseases. The company offers several products that treat rare diseases, including actimmune, which is used to treat chronic granulomatous disease and malignant osteopetrosis, and teprotumumab, a monoclonal antibody used to treat thyroid eye disease. The company also offers several rheumatology products such as KRYSTEXXA, a medication for refractory gout.
Horizon Therapeutics is committed to expanding its capabilities in the rare disease space. The company has a strong pipeline of products in various stages of development, including drugs approved by the FDA for many orphan diseases. The company is focused on the development of innovative treatments for rare diseases where there is a significant unmet need.
Horizon Therapeutics has a global presence, with operations in North America and Europe. The company has collaborations with several pharmaceutical companies to expand its portfolio and develop new drugs. They have agreements with HemoShear Therapeutics, Inc., and River Vision Development Corporation.
Horizon Therapeutics has a strong financial position, with total revenue of $2.4 billion in 2019. The company is committed to creating value for its shareholders, and it has grown exponentially over the years.
In conclusion, Horizon Therapeutics is a biopharmaceutical company committed to improving the lives of people living with rare and rheumatic diseases. With a strong pipeline and collaborations with other pharmaceutical companies, Horizon Therapeutics is well-positioned for continued growth and success into the future.
Company Address: 70 St. Stephen’s Green Dublin 2 0
Company Phone Number: 353 1 772 2100 Stock Exchange / Ticker: NASDAQ HZNP
|
%
1.4%